Status:
COMPLETED
FLIO and the Influence of Oral Lutein Supplementation on Macular Pigment
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Age Related Macular Degeneration
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To investigate the effects of lutein supplementation on macular pigment density using FLIO and MPOD measurements in patients with age-related macular degeneration and healthy subjects over a course of...
Detailed Description
The human macula is a small area of the retina responsible for central vision. The yellow macular pigment contains three carotenoids, lutein ((3R,3'R,6'R)-lutein), zeaxanthin ((3R,3'R)-zeaxanthin), an...
Eligibility Criteria
Inclusion
- Subject must be willing to give written informed consent
- Probands 18 years of age or greater
- Both eyes will be assessed in the study
Exclusion
- Opacities of ocular media excluding detailed observation of the retina
- Gastrointestinal diseases that could cause disturbance of dietary absorption
- History of lutein supplementation
- Allergy to lutein and zeaxanthin
- Missing compliance
Key Trial Info
Start Date :
June 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 22 2019
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04761341
Start Date
June 1 2018
End Date
October 22 2019
Last Update
January 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Ophthalmology, Inselspital, Bern University Hostpital, University of Bern, Bern, Switzerland
Bern, Switzerland, 3010